| Autor: |
Teicher, Beverly A., Disis, Mary L., Bhattacharya-Chatterjee, Malaya, Rohatgi, Nitin, Chatterjee, Sunil K., Saha, Asim, Shukla, Rakesh, Foon, Kenneth A. |
| Zdroj: |
Immunotherapy of Cancer; 2006, p139-149, 11p |
| Abstrakt: |
Certain anti-idiotypic (Id) antibodies that bind to the antigen-combining sites of antibodies can effectively mimic the three-dimensional structures and functions of the external antigens and can be used as surrogate antigens for active specific immunotherapy. Several monoclonal anti-Id antibodies that mimic distinct human tumor-associated antigens have been developed and characterized by others and us. CeaVac (anti-Id 3H1) is an internal image anti-Id antibody that mimics a distinct and specific epitope of carcinoembryonic antigen (CEA) and can be used as a surrogate for CEA. Extensive preclinical studies, as well as results obtained from clinical trials, suggest that vaccination with 3H1 has the potential to augment survival benefits. Anti-Id 3H1 easily breaks immune tolerance to CEA and induces anti-CEA antibody, as well as CD4+ T-helper, responses in colorectal cancer patients and also in mice transgenic for CEA. This chapter summarizes the science behind the development of anti-Id 3H1 and updates our clinical experience that includes all the patients entered on the study thus far. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
